Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen Y, Colao A. Sheppard M, et al. Among authors: bronstein md. Pituitary. 2015 Jun;18(3):395-6. doi: 10.1007/s11102-014-0628-z. Pituitary. 2015. PMID: 25566750 Free PMC article. No abstract available.
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen Y, Colao A. Sheppard M, et al. Among authors: bronstein md. Pituitary. 2015 Jun;18(3):385-94. doi: 10.1007/s11102-014-0585-6. Pituitary. 2015. PMID: 25103549 Free PMC article. Clinical Trial.
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M; Pasireotide C2305 Study Group. Colao A, et al. Among authors: bronstein md. J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. doi: 10.1210/jc.2013-2480. Epub 2014 Jan 13. J Clin Endocrinol Metab. 2014. PMID: 24423324 Free PMC article. Clinical Trial.
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, Shen CC, Gadelha M, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Freda P; Pasireotide C2305 Study Group. Bronstein MD, et al. BMC Endocr Disord. 2016 Apr 2;16:16. doi: 10.1186/s12902-016-0096-8. BMC Endocr Disord. 2016. PMID: 27039081 Free PMC article. Clinical Trial.
Medical combination therapies in Cushing's disease.
Vilar L, Naves LA, Machado MC, Bronstein MD. Vilar L, et al. Among authors: bronstein md. Pituitary. 2015 Apr;18(2):253-62. doi: 10.1007/s11102-015-0641-x. Pituitary. 2015. PMID: 25647330
Challenges in the diagnosis and management of acromegaly: a focus on comorbidities.
Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CM, Pinedo AC, Guerrero DP, Barrera CA, Franco HI, Ribeiro-Oliveira A Jr, Vilar L, Jallad RS, Duarte FG, Gadelha M, Boguszewski CL, Abucham J, Naves LA, Musolino NR, de Faria ME, Rossato C, Bronstein MD. Abreu A, et al. Among authors: bronstein md. Pituitary. 2016 Aug;19(4):448-57. doi: 10.1007/s11102-016-0725-2. Pituitary. 2016. PMID: 27279011 Free PMC article. Review.
Management of prolactinomas in Brazil: an electronic survey.
Vilar L, Naves LA, Casulari LA, Azevedo MF, Albuquerque JL, Serfaty FM, Pinho Barbosa FR, de Oliveira AR Jr, Montenegro RM, Montenegro RM Jr, Ramos AJ, Dos Santos Faria M, Musolino NR, Gadelha MR, Boguszewski CL, Bronstein MD. Vilar L, et al. Among authors: bronstein md. Pituitary. 2010 Sep;13(3):199-206. doi: 10.1007/s11102-010-0217-8. Pituitary. 2010. PMID: 20107911
Management of acromegaly in Latin America: expert panel recommendations.
Barkan A, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-Monteros AL, Gadelha MR, Garavito G, Guitelman M, Mangupli R, Mercado M, Portocarrero L, Sheppard M. Barkan A, et al. Among authors: bronstein md. Pituitary. 2010 Jun;13(2):168-75. doi: 10.1007/s11102-009-0206-y. Pituitary. 2010. PMID: 19882249 Free PMC article. Review.
Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
Neggers SJ, Pronin V, Balcere I, Lee MK, Rozhinskaya L, Bronstein MD, Gadelha MR, Maisonobe P, Sert C, van der Lely AJ; LEAD Study Group. Neggers SJ, et al. Among authors: bronstein md. Eur J Endocrinol. 2015 Sep;173(3):313-23. doi: 10.1530/EJE-15-0215. Epub 2015 Jun 5. Eur J Endocrinol. 2015. PMID: 26047625 Free PMC article.
169 results